

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

NCI-H522

RRID:CVCL_1567

Type: Cell Line

Proper Citation

RRID:CVCL_1567

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1567

Proper Citation: RRID:CVCL_1567

Description: Cell line NCI-H522 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:1563005](#), [PMID:1565469](#), [PMID:2041050](#), [PMID:2388294](#), [PMID:3335022](#), [PMID:7718330](#), [PMID:8806092](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:11030152](#), [PMID:15748285](#), [PMID:15900046](#), [PMID:17088437](#), [PMID:18277095](#), [PMID:19153074](#), [PMID:19372543](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22068913](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:22961666](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30710758](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Donor information: Established from a 60 packs per year smoker (ATCC=CRL-5810)., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H522

Synonyms: NCI.H522, H522, H-522, NCI-522, NCI522, NCIH522

Cross References: BTO:BTO_0003536, CLO:CLO_0008094, EFO:EFO_0002295, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5810, BioSample:SAMN03471314, BioSample:SAMN10988279, cancercellines:CVCL_1567, Cell_Model_Passport:SIDM00116, ChEMBL-Cells:ChEMBL3308392, ChEMBL-Targets:ChEMBL614387, CLS:305279, Cosmic:875853, Cosmic:877409, Cosmic:897509, Cosmic:903576, Cosmic:905944, Cosmic:974294, Cosmic:980965, Cosmic:1004696, Cosmic:1032437, Cosmic:1044246, Cosmic:1092622, Cosmic:1146919, Cosmic:1154592, Cosmic:1175866, Cosmic:1188591, Cosmic:1219062, Cosmic:1239883, Cosmic:1305350, Cosmic:1312335, Cosmic:1436012, Cosmic:1802320, Cosmic:1870276, Cosmic:1891886, Cosmic:1995582, Cosmic:1998464, Cosmic:2125185, Cosmic:2772155, Cosmic-CLP:905944, DepMap:ACH-000343, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905944, GEO:GSM2101, GEO:GSM50217, GEO:GSM50280, GEO:GSM206495, GEO:GSM274753, GEO:GSM274754, GEO:GSM353230, GEO:GSM434309, GEO:GSM513965, GEO:GSM514350, GEO:GSM743456, GEO:GSM750798, GEO:GSM784233, GEO:GSM794291, GEO:GSM799344, GEO:GSM799407, GEO:GSM827479, GEO:GSM847077, GEO:GSM887434, GEO:GSM888514, GEO:GSM1153415, GEO:GSM1178491, GEO:GSM1178492, GEO:GSM1181345, GEO:GSM1181346, GEO:GSM1374751, GEO:GSM1374752, GEO:GSM1374753, GEO:GSM1670248, GEO:GSM2124677, IARC_TP53:520, IARC_TP53:21410, IGRhCellID:NCIH522, KCLB:25810, KCLB:90522, LiGeA:CCLE_084, LINCS_LDP:LCL-1622, NCI-DTP:NCI-H522, PharmacDB:NCIH522_1118_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD011315, PRIDE:PXD030304, Progenetix:CVCL_1567, PubChem_Cell_line:CVCL_1567, SKY/M-FISH/CGH:2803, Wikidata:Q54908074

ID: CVCL_1567

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260905T181246+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H522.

Warning: Discontinued: KCLB; 25810

Donor information: Established from a 60 packs per year smoker (ATCC=CRL-5810)., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Chuikov S, et al. (2026) E2A selectively regulates TGF- β -induced apoptosis in KRAS-mutant non-small cell lung cancer. *Molecular oncology*, 20(7), 1877.

Ren D, et al. (2026) Gasdermin C reprograms metabolism through the CAMKK2-AMPK axis to promote lung adenocarcinoma progression and radioresistance. *Cell reports*, 45(6), 117427.

Arora P, et al. (2025) Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D. *Journal of virology*, 99(2), e0123024.

Gesmundo I, et al. (2025) Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells. *International journal of molecular sciences*, 26(7).

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Srivastava PP, et al. (2025) Epigenetic co-regulator HCF-1 promotes lung cancer via O-GlcNAcylation-dependent pathways. *Molecular therapy. Oncology*, 33(4), 201046.

Zhang L, et al. (2024) ACE2-independent sarbecovirus cell entry can be supported by TMPRSS2-related enzymes and can reduce sensitivity to antibody-mediated neutralization. *PLoS pathogens*, 20(11), e1012653.

Geroyska S, et al. (2024) N-Myristoyltransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma. *Cancer research communications*, 4(7), 1815.

Horie M, et al. (2024) Exosomes secreted by ST3GAL5^{high} cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment. *Molecular oncology*, 18(1), 21.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Kweon TH, et al. (2024) O-GlcNAcylation of RBM14 contributes to elevated cellular O-GlcNAc through regulation of OGA protein stability. *Cell reports*, 43(5), 114163.

Ando T, et al. (2024) NECTIN2 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma. *Respiratory investigation*, 62(4), 582.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Lal S, et al. (2023) Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor. *Cancer research*

communications, 3(9), 1731.

Chow A, et al. (2023) The ectonucleotidase CD39 identifies tumor-reactive CD8+ T??cells predictive of immune checkpoint blockade efficacy in human lung cancer. *Immunity*, 56(1), 93.

Kennedy PR, et al. (2023) A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. *Frontiers in immunology*, 14, 1060905.

Sun L, et al. (2022) Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non-Small Cell Lung Cancer Cells. *Molecular cancer research : MCR*, 20(12), 1785.

Puray-Chavez M, et al. (2021) Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. *Cell reports*, 36(2), 109364.

Caeser R, et al. (2021) MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. *iScience*, 24(11), 103224.

Cui C, et al. (2021) Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. *Cell*, 184(12), 3163.